Yapalı, S. 2021. EFFECT OF TENOFOVIR ALAFENAMIDE FUMARATE (TAF) PROPHYLAXIS FOR HEPATITIS B VIRUS REACTIVATION IN HBV-INFECTED INDIVIDUALS, WHO RECEIVED CHEMO/IMMUNOSUPPRESSIVE THERAPY. AASLD_TASL Digital Hepatology Connect , 3-4.

Yapalı, S., (2021). EFFECT OF TENOFOVIR ALAFENAMIDE FUMARATE (TAF) PROPHYLAXIS FOR HEPATITIS B VIRUS REACTIVATION IN HBV-INFECTED INDIVIDUALS, WHO RECEIVED CHEMO/IMMUNOSUPPRESSIVE THERAPY . AASLD_TASL Digital Hepatology Connect (pp.3-4).

Yapalı, Suna. "EFFECT OF TENOFOVIR ALAFENAMIDE FUMARATE (TAF) PROPHYLAXIS FOR HEPATITIS B VIRUS REACTIVATION IN HBV-INFECTED INDIVIDUALS, WHO RECEIVED CHEMO/IMMUNOSUPPRESSIVE THERAPY," AASLD_TASL Digital Hepatology Connect, 2021

Yapalı, Suna. "EFFECT OF TENOFOVIR ALAFENAMIDE FUMARATE (TAF) PROPHYLAXIS FOR HEPATITIS B VIRUS REACTIVATION IN HBV-INFECTED INDIVIDUALS, WHO RECEIVED CHEMO/IMMUNOSUPPRESSIVE THERAPY." AASLD_TASL Digital Hepatology Connect , pp.3-4, 2021

Yapalı, S. (2021) . "EFFECT OF TENOFOVIR ALAFENAMIDE FUMARATE (TAF) PROPHYLAXIS FOR HEPATITIS B VIRUS REACTIVATION IN HBV-INFECTED INDIVIDUALS, WHO RECEIVED CHEMO/IMMUNOSUPPRESSIVE THERAPY." AASLD_TASL Digital Hepatology Connect , pp.3-4.

@conferencepaper{conferencepaper, author={Suna YAPALI}, title={EFFECT OF TENOFOVIR ALAFENAMIDE FUMARATE (TAF) PROPHYLAXIS FOR HEPATITIS B VIRUS REACTIVATION IN HBV-INFECTED INDIVIDUALS, WHO RECEIVED CHEMO/IMMUNOSUPPRESSIVE THERAPY}, congress name={AASLD_TASL Digital Hepatology Connect}, city={}, country={}, year={2021}, pages={3-4} }